Background
Methods
Study setting and participants
Data collection and measurements
Ethical considerations
Data analysis
Results
Demographic characteristics of participants
Variables | HAART experienced Group (n = 157) | HAART-naïve Group (n = 52) | Total | p-value | |
---|---|---|---|---|---|
Gender | Male, n(%) | 34 (21.7) | 17 (32.7) | 51 (24.4) | |
Female, n(%) | 123 (78.3) | 35 (67.3) | 158 (75.6) | ||
Age (years) | Mean ± SD | 44.9 (10.7) | 38.8 (10.8) | 43.4 (11.0) | 0.0002 |
21-30 years, n(%) | 12 (7.6) | 12 (23.1) | 24 (11.5) | ||
31-40 years, n(%) | 48 (30.6) | 19 (36.5) | 67 (32.1) | ||
41-50 years, n(%) | 52 (33.1) | 15 (28.8) | 67 (32.1) | ||
> 50 years, n(%) | 45 (28.7) | 6 (11.5) | 51 (24.4) | ||
BMI (kg/m2) | Mean ± SD | 27.0 (5.4) | 25.3 (4.6) | 26.6 (5.3) | 0.0188 |
< 18 kg/m2, n(%) | 3 (1.9) | 1 (1.9) | 4 (1.9) | ||
18-24.9 kg/m2, n(%) | 64 (40.8) | 2548.1) | 89 (42.6) | ||
25.0-29.9 kg/m2, n(%) | 50 (31.8) | 18 (34.6) | 68 (32.5) | ||
≥ 30 kg/m2, n(%) | 40 (25.5) | 8 (15.4) | 48 (23.0) | ||
CD4+ T cell count* | Mean ± SD | 430.3 (301.2) | 411 (222.5) | 424.9 (280.6) | 0.7389 |
< 200 cells\μl | 20 (23.5) | 6 (18.2) | 26 (22.0) | ||
200-499 cells\μl | 36 (42.4) | 14 (42.4) | 50 (42.4) | ||
≥ 500 cells\μl | 29 (34.1) | 13 (39.4) | 42 (35.6) | ||
Alcohol intake | No, n(%) | 131 (83.4) | 40 (76.9) | 171 (81.8) | |
Yes, n(%) | 26 (16.6) | 12 (23.1) | 38 (18.2) | ||
Cigarette smoking | No, n(%) | 154 (98.1) | 51 (98.1) | 205 (98.1) | |
Yes, n(%) | 03 (1.9) | 01 (1.9) | 04 (1.9) | ||
Hypertension | Not present, n(%) | 118 (75.2) | 45 (86.5) | 163 (78.0) | |
Present, n(%) | 39 (24.8) | 07 (13.5) | 46 (22.0) | ||
Diabetes Mellitus | Not present, n(%) | 154 (98.1) | 50 (96.2) | 204 (97.6) | |
Present, n(%) | 03 (1.9) | 02 (3.8) | 05 (2.4) | ||
Obesity | Not present, n(%) | 117 (74.5) | 44 (84.6) | 161 (77.0) | |
Present, n(%) | 40 (25.5) | 08 (15.2) | 48 (23.0) |
Dyslipidemia and characteristics of lipid profiles
Parameters | HAART experienced Group (n = 157) | HAART naïve Group (n = 52) | p-value |
---|---|---|---|
Total cholesterol, mean ± SD | 208.7 (71.9) | 147.4 (44.6) | < 0.0001 |
≥ 200 mg/dL | 80 (51.0 %) | 5 (9.6 %) | < 0.0001 |
LDL-cholesterol, mean ± SD | 117.6 (68.2) | 65.9 (42.0) | < 0.0001 |
≥ 130 mg/dL | 58 (36.9 %) | 4 (7.7 %) | 0.0001 |
HDL-cholesterol, mean ± SD | 67.0 (62.6) | 62.5 (26.3) | 0.6153 |
< 40 mg/dL | 22 (14.0 %) | 7 (13.5 %) | 0.9257 |
Triglycerides, mean ± SD | 117.2 (59.3) | 97.7 (57.5) | 0.0396 |
≥ 150 mg/dL | 32 (20.4 %) | 9 (17.3 %) | 0.6257 |
TC/HDL-cholesterol ratio, mean ± SD | 3.7 (2.6) | 2.8 (1.7) | 0.0205 |
≥ 5 | 24 (15.3 %) | 3 (5.8 %) | 0.0769 |
Total cholesterol and triglyceride levels differed among the HAART regimens
NRTIs based regimens | |||
---|---|---|---|
Lipid profile | AZT based (n = 82) | TDF based (n = 75) | p-value |
Total cholesterol, mean ± SD | 205.2 (66.3) | 212.3 (77.8) | 0.540 |
≥ 200 mg/dL | 41 (50.0 %) | 39 (52.0 %) | 0.802 |
LDL-cholesterol, mean ± SD | 115.9 (63.2) | 119.5 (73.6) | 0.744 |
≥ 130 mg/dL | 27 (32.9 %) | 31 (41.3 %) | 0.276 |
HDL-cholesterol, mean ± SD | 70.1 (29.9) | 63.7 (25.6) | 0.153 |
< 40 mg/dL | 13 (15.9 %) | 9 (12.0 %) | 0.482 |
Triglycerides, mean ± SD | 102.4 (46.9) | 133.4 (67.1) | 0.009 |
≥ 150 mg/dL | 12 (14.6 %) | 20 (26.7 %) | 0.060 |
TC/HDL-cholesterol ratio, mean ± SD | 3.6 (2.7) | 3.9 (2.4) | 0.405 |
≥ 5 | 12 (14.6 %) | 12 (16.0 %) | 0.808 |
NNRTIs based regimens | |||
NVP based (n = 101) | EFV based (n = 43) | ||
Total cholesterol, mean ± SD | 204.1 (65.5) | 218.7 (90.6) | 0.282 |
≥ 200 mg/dL | 49 (48.5 %) | 23 (53.5 %) | 0.583 |
LDL-cholesterol, mean ± SD | 114.6 (61.2) | 126.5 (87.7) | 0.353 |
≥ 130 mg/dL | 36 (35.6 %) | 17 (39.5 %) | 0.657 |
HDL-cholesterol, mean ± SD | 68.3 (29.5) | 63.8 (22.5) | 0.370 |
< 40 mg/dL | 17 (16.8 %) | 3 (7.0 %) | 0.119 |
Triglycerides, mean ± SD | 105.4 (29.5) | 136.0 (75.4) | 0.004 |
≥ 150 mg/dL | 15 (14.9 %) | 12 (27.9 %) | 0.068 |
TC/HDL-cholesterol ratio, mean ± SD | 3.6 (2.7) | 3.9 (2.3) | 0.635 |
≥ 5 | 16 (15.8 %) | 7 (16.3 %) | 0.940 |
Dyslipidemia with CD4+ T cell count, hypertension, diabetes mellitus and obesity
Association of gender, BMI, HIV duration and HAART use with abnormal lipid profiles
Explanatory variables | TC ≥ 200 mg/dL UOR (95 % CI) | LDL-c ≥ 130 mg/dL UOR (95 % CI) | HDL-c < 40 mg/dL UOR (95 % CI) | TG ≥ 150 mg/dL UOR (95 % CI) |
---|---|---|---|---|
Gender (Female) | 2.3 (1.03-4.98) | 1.29 (0.58-2.89) | 0.54 (0.20-1.44) | 0.52 (0.22-1.25) |
p-value | 0.042 | 0.532 | 0.217 | 0.144 |
Age > 40 years | 0.81 (0.43-1.56) | 1.18 (0.61-2.31) | 0.93 (0.36-2.37) | 0.70 (0.30-1.60) |
p-value | 0.535 | 0.621 | 0.879 | 0.391 |
BMI ≥ 25 kg/m2 | 0.80 (0.42-1.51) | 0.82 (0.43-1.59) | 0.92 (0.37-2.30) | 0.30 (0.12-0.75) |
p-value | 0.490 | 0.558 | 0.857 | 0.010 |
CD4+ T cell count < 200 cells/μl | 0.80 (0.29-2.17) | 0.72 (0.26-1.97) | 0.58 (0.13-2.55) | 0.64 (0.17-2.36) |
p-value | 0.652 | 0.518 | 0.468 | 0.506 |
HIV duration ≥ 42 months | 0.51 (0.26-0.99) | 0.59 (0.29-1.18) | 0.66 (0.24-1.79) | 0.36 (0.14-0.93) |
p-value | 0.045 | 0.136 | 0.413 | 0.035 |
HAART duration > 55 months | 0.47 (0.25-0.90) | 0.58 (0.30-1.11) | 0.77 (0.31-1.92) | 0.31 (0.13-0.74) |
p-value | 0.022 | 0.101 | 0.572 | 0.008 |
Hypertension | 1.02 (0.49-2.10) | 0.94 (0.44-2.00) | 0.87 (0.30-2.54) | 0.81 (0.32-2.06) |
p-value | 0.962 | 0.876 | 0.805 | 0.664 |
Diabetes Mellitus | 0.47 (0.04-5.34) | 0.85 (0.08-9.59) | NA | 8.27 (0.73-94.2) |
p-value | 0.546 | 0.896 | NA | 0.089 |
Obesity | 1.88 (0.90-3.92) | 2.08 (1.00-4.32) | 1.11 (0.40-3.08) | 1.44 (0.61-3.38) |
p-value | 0.093 | 0.050 | 0.835 | 0.403 |
Alcohol intake | 1.38 (0.59-3.24) | 0.72 (0.29-1.78) | 1.14 (0.35-3.70) | 2.49 (0.99-6.27) |
p-value | 0.453 | 0.476 | 0.825 | 0.054 |
Explanatory Variables | TC ≥ 200 mg/dL AOR (95 % CI) | LDL-c ≥ 130 mg/dL AOR (95 % CI) | HDL-c < 40 mg/dL AOR (95 % CI) | TG ≥ 150 mg/dL AOR (95 % CI) | TC/HDL-c ≥ 5 AOR (95 % CI) |
---|---|---|---|---|---|
Antiretroviral therapy | |||||
HAART-naïve* | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
HAART treated | 6.24 (2.33-17.45) | 5.28 (1.17-16.32) | 1.07 (0.37-3.05) | 0.86 (0.32-2.28) | 2.51 (0.64-9.89) |
p-value | < 0.001 | 0.004 | 0.904 | 0.762 | 0.188 |
Gender | |||||
Male* | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
Female | 2.17 (0.99-4.74) | 1.20 (0.55-2.65) | 0.45 (0.19-1.07) | 0.44 (0.19-1.01) | 0.42 (0.16-1.09) |
p-value | 0.053 | 0.645 | 0.071 | 0.054 | 0.076 |
Age group | |||||
≤ 40 years* | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
> 40 years | 1.11 (0.58-2.31) | 0.91 (0.47-1.78) | 0.80 (0.35-1.84) | 1.22 (0.57-2.58) | 1.02 (0.42-2.46) |
p-value | 0.746 | 0.789 | 0.605 | 0.611 | 0.963 |
Body Mass Index | |||||
BMI < 25 kg/m2* | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
BMI ≥ 25 kg/m2 | 0.98 (0.52-1.86) | 1.07 (0.56-2.05) | 0.88 (0.39-1.98) | 3.25 (1.44-7.34) | 2.19 (0.87-5.51) |
p-value | 0.962 | 0.845 | 0.757 | 0.005 | 0.097 |
HIV duration | |||||
< 42 months* | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
≥ 42 months | 2.26 (1.16-4.42) | 1.71 (0.85-3.45) | 1.32 (0.53-3.29) | 1.89 (0.81-4.41) | 1.58 (0.60-4.13) |
p-value | 0.017 | 0.133 | 0.0.545 | 0.140 | 0.350 |